Jha S, Simonds WF (2023) Molecular and clinical spectrum of primary hyperparathyroidism. Endocr Rev 44(5):779–818

Article  PubMed  PubMed Central  Google Scholar 

Halperin R, Arnon L, Nasirov S, Friedensohn L, Gershinsky M, Telerman A et al (2022) Germline CDKN1B variant type and site are associated with phenotype in MEN4. Endocr Relat Cancer 30:e220174

PubMed  Google Scholar 

Chevalier B, Coppin L, Romanet P, Cuny T, Maïza JC, Abeillon J et al (2024) Beyond MEN1, when to think about MEN4? Retrospective study on 5600 patients in the French population and literature review. J Clin Endocrinol Metab 1–12

Seabrook AJ, Harris JE, Velosa SB, Kim E, McInerney-Leo AM, Dwight T et al (2021) Multiple endocrine tumors associated with germline MAX mutations: multiple endocrine neoplasia type 5? J Clin Endocrinol Metab 106(4):1163–1182

Article  PubMed  Google Scholar 

Marx SJ, Goltzman D (2019) Evolution of our understanding of the hyperparathyroid syndromes: a historical perspective. J Bone Min Res 34(1):22–37

Article  Google Scholar 

Nesbit MA, Hannan FM, Howles SA, Babinsky VN, Head RA, Cranston T et al (2013) Mutations affecting G-protein subunit α 11 in hypercalcemia and hypocalcemia. N Engl J Med 368(26):2476–2486

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nesbit MA, Hannan FM, Howles SA, Reed AAC, Cranston T, Thakker CE et al (2013) Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3. Nat Genet 45(1):93–97

Article  CAS  PubMed  Google Scholar 

Wermer P (1954) Genetic aspects of adenomatosis of endocrine glands. Am J Med 16(3):363–371

Article  CAS  PubMed  Google Scholar 

Thakker R V, Newey PJ, Walls G V, Bilezikian J, Dralle H, Ebeling PR et al (2012) Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 97(9):2990–3011. http://www.ncbi.nlm.nih.gov/pubmed/22723327

Machens A, Schaaf L, Karges W, Frank-Raue K, Bartsch DK, Rothmund M et al (2007) Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin Endocrinol (Oxf) 67(4):613–622

Article  PubMed  Google Scholar 

Kamilaris CDC, Stratakis CA (2019) Multiple endocrine neoplasia type 1 (MEN1): an update and the significance of early genetic and clinical diagnosis. Front Endocrinol (Lausanne) 10:1–15

Article  Google Scholar 

Trump D, Farren B, Wooding C, Pang J, Besser G, Buchanan K et al (1996) Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Q J Med 89:653–669

Article  CAS  Google Scholar 

Twigt BA, Scholten A, Valk GD, Rinkes IHMB, Vriens MR (2013) Differences between sporadic and MEN related primary hyperparathyroidism; clinical expression, preoperative workup, operative strategy and follow-up. Orphanet J Rare Dis 8(1):50. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3623824&tool=pmcentrez&rendertype=abstract

Eller-Vainicher C, Chiodini I, Battista C, Viti R, Mascia ML, Massironi S et al (2009) Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res 24(8):1404–1410

Article  PubMed  Google Scholar 

Goudet P, Dalac A, Le Bras M, Cardot-Bauters C, Niccoli P, Lévy-Bohbot N et al (2015) MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d’étude des Tumeurs Endocrines. J Clin Endocrinol Metab 100(4):1568–1577

Article  CAS  PubMed  Google Scholar 

Yavropoulou MP, Vlachou S, Tsoli M, Fostira F, Kaltsas G, Kassi E (2022) Management and long-term follow-up of hyperparathyroidism in multiple endocrine neoplasia type 1: single center experience. J Clin Med 11(7):1–11

Article  Google Scholar 

Thakker RV (2014) Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol 386(1–2):2–15. https://doi.org/10.1016/j.mce.2013.08.002

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tonelli F, Marcucci T, Fratini G, Tommasi MS, Falchetti A, Brandi ML (2007) Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann Surg 246(6):1075–1082

Article  PubMed  Google Scholar 

Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE, Marcocci C, Minisola S et al (2022) Evaluation and management of primary hyperparathyroidism : summary statement and guidelines from the fifth international workshop. J Bone Miner Res 37(12):2568–2585

PubMed  Google Scholar 

De Menezes Montenegro FL, Brescia MDEG, Lourenço DM, Arap SS, D’Alessandro AF, De Britto E Silva Filho G et al (2019) Could the less-than subtotal parathyroidectomy be an option for treating young patients with multiple endocrine neoplasia type 1-related hyperparathyroidism? Front Endocrinol (Lausanne) 10:1–10

Choi HR, Choi SH, Choi SM, Kim JK, Lee CR, Kang SW et al (2020) Benefit of diverse surgical approach on short-term outcomes of MEN1-related hyperparathyroidism. Sci Rep 10(1):1–7

Google Scholar 

Brandi M, Agarwal S, Perrier N, Lines K, Valk G, Thakker R (2021) Multiple endocrine neoplasia type 1: latest insights. Endocr Rev 42(2):133–170

Article  PubMed  Google Scholar 

Mai HD, Sanowski RA (1992) Regression of duodenal gastrinomas in a patient with multiple endocrine neoplasia type I after parathyroidectomy. Gastrointest Endosc 38(6):706–708

Article  CAS  PubMed  Google Scholar 

Nastos C, Papaconstantinou D, Kofopoulos-Lymperis E, Peppa M, Pikoulis A, Lykoudis P et al (2021) Optimal extent of initial parathyroid resection in patients with multiple endocrine neoplasia syndrome type 1: a meta-analysis. Surg (United States) 169(2):302–310

Google Scholar 

Bouriez D, Gronnier C, Haissaguerre M, Tabarin A, Najah H (2022) Less than subtotal parathyroidectomy for multiple endocrine neoplasia type 1 primary hyperparathyroidism: a systematic review and meta-analysis. World J Surg 46(11):2666–2675

Article  PubMed  Google Scholar 

Iacobone M, Carnaille B, Palazzo FF, Vriens M (2015) Hereditary hyperparathyroidism—a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbeck’s Arch Surg 400(8):867–886

Article  Google Scholar 

Goudet P, Cadiot G, Barlier A, Baudin E, Borson-Chazot F, Brunaud L et al (2024) French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d’étude des Tumeurs Endocrines/Association Francophonede Chirurgie Endocrinienne/Reseau national de prise en charge des tumeurs endocrines) for the screening, diagnosis and management of Multiple Endocrine Neoplasia Type 1. Ann Endocrinol (Paris) 85(1):2–19

Article  PubMed  Google Scholar 

Kluijfhout WP, Beninato T, Drake FT, Vriens MR, Gosnell J, Shen WT et al (2016) Unilateral clearance for primary hyperparathyroidism in selected patients with multiple endocrine neoplasia type 1. World J Surg 40(12):2964–2969

Article  PubMed  PubMed Central  Google Scholar 

Moyes VJ, Monson JP, Chew SL, Akker SA (2010) Clinical use of cinacalcet in MEN1 hyperparathyroidism. Int J Endocrinol 2010:10–13

Article  Google Scholar 

Eastell R, Brandi ML, Costa AG, D’Amour P, Shoback DM, Thakker RV (2014) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metab 99(10):3570–3579

Article  CAS  PubMed  Google Scholar 

Giusti F, Cianferotti L, Gronchi G, Cioppi F, Masi L, Faggiano A et al (2016) Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to multiple endocrine neoplasia syndrome type 1 (MEN1). Endocrine 52(3):495–506

Article  CAS  PubMed  Google Scholar 

Saponaro F, Cetani F, Repaci A, Pagotto U, Cipriani C, Pepe J et al (2018) Clinical presentation and management of patients with primary hyperparathyroidism in Italy. J Endocrinol Invest 41(11):1339–1348. https://doi.org/10.1007/s40618-018-0879-z

Article  CAS  PubMed  Google Scholar 

Cetani F, Saponaro F, Banti C, Cianferotti L, Vignali E, Chiavistelli S et al (2012) Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling. J Endocrinol Invest 35(7):655–660

CAS  PubMed  Google Scholar 

Filopanti M, Verga U, Ermetici F, Olgiati L, Eller-Vainicher C, Corbetta S et al (2012) MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly. Eur J Endocrinol 167(2):157–164

Article  CAS  PubMed  Google Scholar 

Donegan D, Singh Ospina N, Rodriguez-Gutierrez R, Al-Hilli Z, Thompson GB, Clarke BL et al (2017) Long-term outcomes in patients with multiple endocrine neoplasia type 1 and pancreaticoduodenal neuroendocrine tumours. Clin Endocrinol (Oxf) 86(2):199–206

Article  CAS  PubMed  Google Scholar 

Van Asselt SJ, Brouwers AH, Van Dullemen HM, Van Der Jagt EJ, Bongaerts AHH, Kema IP et al (2015) EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. Gastrointest Endosc 81(1):159-167.e2. https://doi.org/10.1016/j.gie.2014.09.037

Article  PubMed  Google Scholar 

Barbe C, Murat A, Dupas B, Ruszniewski P, Tabarin A, Vullierme MP et al (2012) Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1. Dig Liver Dis 44(3):228–234. https://doi.org/10.1016/j.dld.2011.09.014

Article  PubMed  Google Scholar 

Anlauf M, Schlenger R, Perren A, Bauersfeld J, Koch CA, Dralle H et al (2006) Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol 30(5):560–574

Article  PubMed  Google Scholar 

Niederle B, Selberherr A, Bartsch DK, Brandi ML, Doherty GM, Falconi M et al (2021) Multiple endocrine neoplasia type 1 and the pancreas: diagnosis and treatment of functioning and non-functioning pancreatic and duodenal neuroendocrine neoplasia within the MEN1 syndrome—an International Consensus Statement. Neuroendocrinology 111(7):609–630

Article  CAS  PubMed  Google Scholar 

Thomas-Marques L, Murat A, Delemer B, Penfornis A, Cardot-Bauters C, Baudin E et al (2006) Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 101(2):266–273

Article  PubMed  Google Scholar 

Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski P et al (2010) Risk factors and causes of death in men1 disease. A GTE (Groupe d’etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 34(2):249–255

Liu X, Chen B, Chen J, Su Z, Sun S (2023) The incidence, prevalence, and survival analysis of pancreatic neuroendocrine tumors in the United States. J Endocrinol Invest 46(7):1373–1384

Article  CAS